The purpose of this Gynecologic Oncology Group study is to evaluate the safety and effectiveness of the drug trametinib given alone and with GSK2141795 in patients with endometrial cancer that has returned or continued to grow despite therapy. Trametinib is approved for treating advanced melanoma; its use for endometrial cancer is considered investigational. It works by blocking a protein involved in cancer growth called MEK.
GSK2141795 is an investigational drug designed to inhibit cancer growth by blocking the activity of a protein called AKT. Patients will be randomly assigned to receive trametinib alone or trametinib plus GSK2141795. Both drugs are taken orally (by mouth).
Researchers will also be testing patients’ tumors for the status of their KRAS genes and will see if these treatments work differently in patients with normal versus mutated KRAS.